Hematologic Malignancy Center

At the Hematologic Malignancy Center, specialists come together from the Division of Hematology and Oncology, the Department of Laboratory Medicine and Genetics, the Department of Pathology, and the Department of Radiation Oncology and provide the best possible and most recent treatment for hematologic malignancy like lymphoma and multiple myeloma. Our goal is to become the best hematologic malignancy center in Asia both for our patients and colleagues by offering the most appropriate treatment and continuing cutting-edge clinical and basic research.

Major areas of treatment / Clinics

Acute and chronic leukemia, anemia aplastic, Hodgkin's disease, non-Hodgkin's lymphoma, myelodysplastic syndrome, multiple myeloma, etc.

Strong points

  • The Center is developing new treatment methods including cytotherapy agents and participating in multinational clinical studies in various phases to introduce the latest medicines to Korea.
  • We guarantee the best patient care thanks to our multi-disciplinary treatment and diagnosis approach. The Division of Hematologic Malignancy Center focuses on the best possible care and research including new drug clinical trials, while the Department of Radiation Oncology is in charge of whole-body irradiation for stem cell transplantation and preventive whole-brain radiotherapies. The Department of Laboratory Medicine and Genetics works on lab tests such as bone marrow examination, chromosome analysis, FISH, and flow cytometry, and the Department of Pathology makes a diagnosis using the latest technology of immunopathology and molecular pathology.
  • The best nursing service is provided by our skilled inpatient and outpatient nurses, oncology nurse practitioners, transplantation coordinators, and research nurses.

Diagnostic tests

Basic blood testing, bone marrow examination, lymph node examination, CT, MRI, PET-CT, etc.

Latest treatment methods

  • Diverse and latest chemotherapies
  • Hematopoietic stem cell transplantation: allogeneic, autologous, cord blood, or mini
  • Immunotherapeutic and cytotherapeutic agents
  • New drug clinical trials

Recent trends in clinical research

We perform the best possible treatment and research including new drug clinical trials for hematologic malignancy. We are currently conducting a global multi-center alemtuzumab clinical study to apply it to mini-transplantation and minimize the risk of graft-versus-host diseases among acute myelogenous leukemia and myelodysplastic syndrome patients over 50. Also, we are applying dose-intensified chemotherapy to acute lymphoblastic leukemia as part of a domestic multi-center clinical study.

To treat chronic myelogenous leukemia, we are using both first- and second-generation Gleevec as a primary therapy, following global guidelines. At the same time, we are conducting global multi-center clinical trials to improve the therapy efficacy. Among them are comparison of Gleevec to nilotinib and radotinib and application of dasatinib depending on early molecular biological reactions to three-month Gleevec administration.

In case of multiple myeloma, the Center conducts international multi-center clinical trials of new drugs including Velcade and performs the latest stem cell transplantation such as autologous and mini-allogeneic stem cell transplantation. For patients with relapsing lymphoma, we clinically research new drugs and antibody therapies.